- Onconova Therapeutics’ Rigosertib Poster Selected for AACR 2024
- Onconova Therapeutics’ Narazaciclib ASH Poster Highlights Activity in Treatment Resistant Mantle Cell Lymphoma
- Onconova Therapeutics’ Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i’s
- Onconova Therapeutics to Present at NobleCon19, Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference
- Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results
- Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023
- Onconova Therapeutics’ ASH Poster To Focus on Narazaciclib in MCL
- Onconova Expands Leadership Team with Two Key Appointments
- Promising Preclinical Narazaciclib Data Presented at MCL Meeting
- Encouraging Rigosertib Data Presented at EADV as Late Breaker
More ▼
Key statistics
On Wednesday, Onconova Therapeutics Inc (ONTX:NAQ) closed at 0.97, 76.08% above the 52 week low of 0.5509 set on Oct 13, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.93 |
---|---|
High | 0.98 |
Low | 0.92 |
Bid | 0.8005 |
Offer | 0.9669 |
Previous close | 0.97 |
Average volume | 82.17k |
---|---|
Shares outstanding | 21.00m |
Free float | 20.84m |
P/E (TTM) | -- |
Market cap | 20.37m USD |
EPS (TTM) | -0.9628 USD |
Data delayed at least 15 minutes, as of Mar 27 2024 20:00 BST.
More ▼